Apogee Therapeutics (APGE) EBIT (2022 - 2026)
Apogee Therapeutics (APGE) reported EBIT of -$82.8 million for Q1 2026, down 31.18% year-over-year from -$120.3 million in Q1 2025, and down 153.79% on a QoQ basis from $153.9 million in Q4 2025.
Apogee Therapeutics (APGE) has 5 years of EBIT data on file, last reported at -$82.8 million in Q1 2026.
- Quarterly EBIT fell 31.18% year-over-year to -$82.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$73.3 million (down 16.12% YoY) and the FY2025 annual result came in at -$53.7 million, down 40.32% from the prior year.
- EBIT eased to -$82.8 million in Q1 2026 per APGE's latest filing, from $153.9 million in the prior quarter.
- Across five years, EBIT topped out at $153.9 million in Q4 2025 and bottomed at -$82.8 million in Q1 2026.
- The 5-year median for EBIT is -$21.6 million (2023), against an average of -$13.7 million.
- Peak annual rise in EBIT reached 371.02% in 2023, while the deepest fall reached 939.92% in 2023.
- Tracing APGE's EBIT over 5 years: stood at -$14.1 million in 2022, then surged by 371.02% to $38.2 million in 2023, then jumped by 168.88% to $102.7 million in 2024, then soared by 49.76% to $153.9 million in 2025, then slumped by 153.79% to -$82.8 million in 2026.
- Per Business Quant, the three latest APGE EBIT figures stand at -$82.8 million (Q1 2026), $153.9 million (Q4 2025), and -$71.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.97 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -15.76 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 642.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 268.64 Mn |
| 10 | Apogee Therapeutics | 5.53 Bn | 4.47 Bn | - | -82.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -82.77 Mn |
| Dec 31, 2025 | 153.87 Mn |
| Sep 30, 2025 | -71.28 Mn |
| Jun 30, 2025 | -73.17 Mn |
| Mar 31, 2025 | -63.10 Mn |
| Dec 31, 2024 | 102.74 Mn |
| Sep 30, 2024 | -58.69 Mn |
| Jun 30, 2024 | -44.12 Mn |
| Mar 31, 2024 | -38.18 Mn |
| Dec 31, 2023 | 38.21 Mn |
| Sep 30, 2023 | -24.31 Mn |
| Jun 30, 2023 | -18.89 Mn |
| Mar 31, 2023 | -12.66 Mn |
| Dec 31, 2022 | -14.10 Mn |
| Sep 30, 2022 | -10.51 Mn |
| Jun 30, 2022 | -1.82 Mn |